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Human fetal malformations associated with the use of an 
angiotensin II receptor antagonist: Case Report
Malformações fetais associadas ao uso de antagonista dos receptores 
de angiotensina II: Relato de Caso
Introduction: The potential risks related to 
drug exposure during pregnancy represent a 
vast chapter in modern obstetrics and data 
regarding the safety of antihypertensive drugs 
during pregnancy are relatively scarce. Case 
report: A 37-year-old patient discovered 
her fifth pregnancy at our hospital after 26 
weeks and 4 days of gestation. She reported 
a history of hypertension and was currently 
being treated with Losartan. Hospitalization 
was recommended for the patient and further 
evaluation of fetal vitality was performed. On 
the fourth day an ultrasound was performed, 
resulting in a severe oligohydramnios, fetal 
centralization and abnormal ductus venosus. 
After 36 hours, the newborn died. Patholo-
gic evaluation: At autopsy, the skullcap had 
large fontanels and deficient ossification. The 
kidneys were slightly enlarged. A microsco-
pic examination detected underdevelopment 
of the tubules and the presence of some dila-
ted lumens. Immunohistochemical detection 
of epithelial membrane antigen was positive. 
Immunoreactivity of CD 15 was also assayed 
to characterize the proximal tubules, and lu-
men collapse was observed in some regions. 
Discussion: Angiotensin-converting enzyme 
inhibitors (ACEIs) and angiotensin receptor 
antagonists (ARAs) are among the most wi-
dely prescribed drugs for hypertension. They 
are often used by hypertensive women who 
are considering become pregnant. While their 
fetal toxicity in the second or third trimesters 
has been documented, their teratogenic effect 
during the first trimester has only recently 
been demonstrated. Conclusion: Constant 
awareness by physicians and patients should 
be encouraged, particularly in regard to the 
prescription of antihypertensive drugs in wo-
men of childbearing age who are or intend to 
become pregnant.
AbstrAct
Keywords: angiotensin receptor antago-
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Introdução: Os riscos relacionados à ex-
posição de drogas durante a gestação repre-
sentam um vasto capítulo na obstetrícia 
moderna e dados sobre a segurança de dro-
gas anti-hipertensivas são relativamente es-
cassos. Relato do caso: Paciente de 37 anos, 
hipertensa crônica, descobriu a gravidez com 
26 semanas e 4 dias de gestação. Estava em 
uso regular de Losartana. Durante avaliação 
fetal ultrassonográfica, foi relatada a presença 
de grave oligoâmnio associado ao quadro de 
centralização fetal com alteração de ducto 
venoso, e, após 36 horas, verificou-se óbito 
neonatal. Necrópsia: Observou-se calota cra-
niana com fontanelas amplas e ossificação 
deficiente. Rins levemente aumentados de 
volume e, à microscopia, hipodesenvolvimen-
to de túbulos com presença de lúmen dilatado. 
Imunohistoquímica com expressão em túbu-
los distais de antígeno epitelial de membrana. 
Imunoperoxidade com expressão em túbu-
los proximais de CD 15 em células epiteliais 
e colapso de alguns lúmens fora observado. 
Discussão: Inibidores da conversão de angio-
tensina e antagonistas de receptor de angio-
tensina estão entre as drogas mais prescritas 
para hipertensão. Estas drogas são frequente-
mente prescritas para mulheres em idade fér-
til e que pretendem engravidar. Enquanto a 
toxicidade fetal destas, nos segundo e terceiro 
trimestres, já é conhecida, seus efeitos durante 
o primeiro trimestre foi apenas recentemente 
demostrado. Conclusão: A conscientização 
por parte de médicos e pacientes deve ser re-
alizada de rotina, principalmente no que diz 
respeito à prescrição e utilização de drogas 
potencialmente teratogênicas ou fetotóxicas. 
Este cuidado deve ser redobrado para paci-
entes que estão em idade reprodutiva e que 
podem se tornar gestantes em uso rotineiro 
destas medicações.
resumo
Palavras-chave: antagonistas de receptores 
de angiotensina; complicações na gravidez; 
hipertensão; toxicidade.
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IntroductIon
Hypertensive disorders represent a leading cause 
of maternal and perinatal mortality and morbidity 
worldwide.1,2 Furthermore, most of the morbidity 
associated with hypertensive disorders is concentrated 
among pregnancies complicated by pre-eclampsia 
and eclampsia, which are the first and second leading 
causes of maternal death.3 Moreover, for every 
woman who dies, approximately 20 others suffer 
severe morbidity.4
Currently, it is widely accepted that sustained, 
severe hypertension (e.g., blood pressure ≥ 160/110 
mmHg) during pregnancy should be treated, since 
it is considered a risk factor for maternal end-organ 
complications (such, as stroke), independent of 
preeclampsia.5-7 However, insufficient evidence is 
available to guide the optimal use of antihypertensives 
for non-severe hypertension (e.g., blood pressure 
140-159 mmHg/90-109 mmHg) during pregnancy.7,8 
Therefore, treatment of non-severe hypertension 
remains controversial due to the lack of clarity 
regarding benefits and risks for mother and child, as 
well as concerns about fetal programming effects.7,8
cAse report
A 37-year-old patient discovered her fifth pregnancy 
at our hospital after 26 weeks and 4 days of gestation. 
She reported a history of hypertension over the past 
five years, and was currently being treated with 
Losartan (50 mg per day) on a regular basis to maintain 
adequate blood pressure levels. After admission to the 
prenatal services of our hospital, routine tests were 
conducted, and her antihypertensive medication was 
changed to methyldopa.
When ultrasonography (US) was performed, a 
single live fetus was observed in pelvic presentation. 
It had an estimated weight of 1007 g, had a placenta 
grade of 0 according to Granum classification, 
an absence of amniotic fluid was detected, and a 
gestational age of 26 weeks and 4 days was estimated. 
Elective hospitalization was recommended for the 
patient and further evaluation of fetal vitality was 
performed. Corticotherapy was also administered 
with 12 mg betametasona given in two cycles.
On the fourth day of hospitalization, routine 
tests were normal, 24 hours proteinuria assay 
was negative, and the patient’s hypertension was 
adequately controlled. Another US was performed, 
resulting in a gestational estimate of 27 weeks and 
1 day. Pelvic presentation was still observed and the 
estimated weight of the fetus was 918 g. In addition, 
severe oligohydramnios was detected. A Doppler 
examination further revealed fetal centralization with 
abnormal ductus venosus. Magnesium sulfate was 
subsequently administered for neuroprotection of the 
fetus and a cesarean delivery was scheduled.
The delivery was performed with no intercurrence 
and the birth of a male newborn was achieved. The 
newborn weighed 1050 g, had an Apgar score of 1 
and 5 at the first and fifth minutes, and he required 
no neonatal resuscitation or orotracheal intubation 
in the delivery room. However, after 36 hours, the 
newborn progressed to cardiac arrest and died.
pathologiC evaluation
At autopsy, the fetus weighed 1050 g and manifested 
the appropriate dimensions for its gestational age. The 
skullcap had large fontanels and deficient ossification. 
A slight reduction in lung volume was observed (right, 
6.3 g; left, 5.0 g; normal range, 27.0 ± 7.0 g). The kidneys 
were also slightly enlarged (combined weight, 20.3 g; 
normal range, 12.0 ± 4.0 g). Following preservation 
of the kidneys, a microscopic examination further 
detected underdevelopment of the tubules and the 
presence of some dilated lumens (Figure 1) compared 
with normal (Figure 2). Immunohistochemical 
detection of epithelial membrane antigen (EMA) 
(typically performed for distal tubules) was positive 
(Figure 3). Immunoreactivity of CD 15 was also 
assayed to characterize the proximal tubules, and lumen 
collapse was observed in some regions (Figure 4). Brain 
changes secondary to ischemia, including softening of 
the semi-oval center focus of perivascular hemorrhage 
in the head of the caudate nucleus and small hemorrhage 
in the IV ventricle were observed. Foci of hemorrhage 
were also observed in the lungs. However, the other 
organs presented no notable changes.
dIscussIon
The potential risks related to drug exposure during 
pregnancy represent a vast chapter in modern obste-
trics. For patients with hypertension who qualify for 
medication, there are several antihypertensive alter-
natives available for clinical application, and these do 
not appear to have a risk of teratogenicity or fetoto-
xicity.9-11 However, data regarding the safety of an-
tihypertensive drugs during pregnancy are relatively 
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Figure 1. Staining of paraffin-embedded kidney sections by haema-
toxylin and eosin showed normal development of glomerular struc-
tures with a disarray of cortical zone, decreased numbers of tubules, 
abundant mesenchimal tissue, abnormal, irregular size and enlarge 
tubules, and proximal and distal convoluted tubules could not be dis-
tinguished. The tubular structures were lined by hypoplatic epithelial 
cells (cuboidal cells) with prominent lumena. Magnification x100.
Figure 2. Staining of paraffin-embedded kidney sections by haema-
toxylin and eosin show normal renal development in a liveborn fetus 
at 39 weeks gestation. Distal tubules well developed and stained ac-
idofilic by eosin. Magnifications: x100.
Figure 3. Positive immunolabeling of distal tubules using monoclonal 
antibodies raised against anti-epithelial (EMA) showed decreased numbers 
of these structures and poor differentiation. Magnification: x100. 
Figure 4. Immunoperoxidase staining with an anti-CD15 antibody. 
Decreased numbers of proximal tubules and poor differentiation were 
observed. Magnifications: x100.
scarce.9,12 There is evidence from animal studies that 
administration of angiotensin-converting enzyme 
inhibitors (ACEIs) during pregnancy is associated wi-
th fetal toxicity and an increased rate of stillbirths.13 
Treatment with angiotensin receptor antagonists 
(ARAs) has similar risks, and is also associated with 
oligohydramnios, fetal growth retardation, pulmo-
nary hypoplasia, neonatal hypotension, renal failure 
with oliguria/anuria, renal tubular abnormalities, and 
calvarial hypoplasia.14-17
The most widely used ARAs include losartan, can-
desartan, valsartan, and tasosartan,14 and these medica-
tions modulate the renin-angiotensin-aldosterone system 
by selectively blocking type 1 angiotensin II receptors.18
ACEIs and ARAs are among the most widely 
prescribed drugs for hypertension. While their 
fetal toxicity in the second or third trimesters 
has been documented,15,19 their teratogenic effect 
during the first trimester has only recently been 
demonstrated.20,21
In a recent meta-analysis of five observational 
cohorts, including 786 exposed infants and over one 
million controls, first trimester exposure to ACEIs or 
ARAs did not lead to a higher risk of major congenital 
malformations compared to other antihypertensive 
drugs.18 Inadvertent exposure to these drugs in the 
first trimester of pregnancy has also not been found 
to present significant risks for malformations in live 
births, however, higher rates of spontaneous abortion 
have been reported for patients prescribed.10 In 
addition, an increased risk for cardiovascular and 
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central nervous system malformations in infants 
whose mothers were prescribed an ACEI during their 
first trimester was recently reported.22
Given the conflicting data regarding the adverse 
effects of ACEIs and ARAs during pregnancy, the 
authors believe that as a preventive policy, physicians 
should not routinely prescribe these drugs for 
pregnant women, or for women who are considering 
becoming pregnant. Information regarding possible 
adverse events associated with these drugs should 
also be provided to patients, with informed consent 
required for women of childbearing age who elect to 
receive such drugs.
conclusIon
It is known that drugs with possible harmful fetal 
effects are included in the therapeutic armamentarium 
for many diseases, and that it is possible women will 
become pregnant when using these medications. Thus, 
constant awareness by physicians and patients should 
be encouraged, particularly in regard to the prescription 
of antihypertensive drugs in women of childbearing 
age who are or intend to become pregnant.
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